Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.
Adam Penn-NicholsonThomas HrahaEthan G ThompsonDavid SterlingStanley Kimbung MbandiKirsten M WallMichelle FisherSara A SulimanSmitha ShankarWillem A HanekomNebojsa JanjicMark HatherillStefan H E KaufmannJayne S SutherlandKatharina RonacherMary Ann De GrooteUrs OchsnerDaniel E ZakThomas Jens Scribanull nullPublished in: PLoS medicine (2019)
Both proteomic TB risk signatures predicted progression to incident TB within a year of diagnosis. To our knowledge, these are the first validated prognostic proteomic signatures. Neither meet the minimum criteria as defined in the WHO Target Product Profile for a progression test. More work is required to develop such a test for practical identification of individuals for investigation of incipient, subclinical, or active TB disease for appropriate treatment and care.